T-cell/histiocyte-rich large B-cell lymphoma presenting as a primary central nervous system lymphoma

被引：2

作者：

Advani, Pooja ^{[1
]}

Starr, Jason ^{[1
,2
]}

Swaika, Abhisek ^{[1
]}

Jiang, Liuyan ^{[3
]}

Qiu, Yushi ^{[4
]}

Li, Zhimin ^{[4
]}

Tun, Han W. ^{[1
,4
]}

机构：

[1] Mayo Clin, Dept Internal Med, Div Hematol & Oncol, Jacksonville, FL 32224 USA

[2] Canc Specialists North Florida, Jacksonville, FL USA

[3] Mayo Clin, Dept Lab Med & Pathol, Jacksonville, FL 32224 USA

[4] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA

来源：

RARE TUMORS | 2015年 / 7卷 / 04期

关键词：

Central nervous system; diffuse large B-cell lymphoma; osteopontin; T-cell/histiocyterich large B-cell lymphoma;

D O I：

10.4081/rt.2015.6084

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Primary central nervous system (PCNSL) lymphoma is an aggressive extranodal non-Hodgkin lymphoma, and most cases are classified as diffuse large B-cell lymphoma (DLBCL) by histology. T-cell/histiocyte-rich large B-cell lymphoma (TCRLBCL) represents a distinct subtype of diffuse large B-cell lymphoma and is characterized by the presence of scattered large neoplastic B-cells in a background of abundant T-cells and histiocytes. This is in contrast to the dense perivascular cuffing of neoplastic B-cells in classic DLBCL. T-cell/histiocyte-rich large B-cell lymphoma should be considered in PCNSL cases in which neoplastic B-cells are sparse and scattered. Immunohistochemistry will help identify the B-cells and surrounding infiltrate rich in Tlymphocytes and histiocytes. Future studies exploring the biology of TCRLBCL and the crosstalk between the neoplastic cells and the surrounding inflammatory infiltrate may provide exciting prospects for future therapies for TCRLBCL.

引用

页码：160 / 162

页数：3

共 11 条

[1] T-cell/histiocyte-rich B-cell lymphoma: Biology, diagnosis, and management [J].

Abramson, Jeremy S. .

ONCOLOGIST, 2006, 11 (04) :384-392

[2] T-cell/histiocyte-rich large B-cell lymphoma: A distinct clinicopathologic entity [J].

Achten, R ;

Verhoef, G ;

Vanuytsel, L ;

De Wolf-Peeters, C .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1269-1277

[3]

Bhagavathi S, 2008, ARCH PATHOL LAB MED, V132, P1830, DOI 10.1043/1543-2165-132.11.1830

[4] T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: A matched-control analysis [J].

Bouabdallah, R ;

Mounier, N ;

Guettier, C ;

Molina, T ;

Ribrag, V ;

Thieblemont, C ;

Sonet, A ;

Delmer, A ;

Belhadj, K ;

Gaulard, P ;

Gisselbrecht, C ;

Xerri, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1271-1277

[5]

Commins Deborah L, 2006, Neurosurg Focus, V21, pE2

[6]

Dogan A., 2008, WHO CLASSIFICATION T

[7] How I treat primary CNS lymphoma [J].

Ferreri, Andres J. M. .

BLOOD, 2011, 118 (03) :510-522

[8]

Jiang LY, 2012, INT J CLIN EXP PATHO, V5, P72

[9] Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models [J].

Li, Zhimin ;

Qiu, Yushi ;

Personett, David ;

Huang, Peng ;

Edenfield, Brandy ;

Katz, Jason ;

Babusis, Darius ;

Tang, Yang ;

Shirely, Michael A. ;

Moghaddam, Mehran F. ;

Copland, John A. ;

Tun, Han W. .

PLOS ONE, 2013, 8 (08)

[10] Differential gene expression in central nervous system lymphoma [J].

Rubenstein, James L. ;

Shen, Arthur ;

Batchelor, Tracy T. ;

Kadoch, Cigall ;

Treseler, Patrick ;

Shuman, Marc A. .

BLOOD, 2009, 113 (01) :266-267

← 1 2 →